311 related articles for article (PubMed ID: 32804298)
1. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
4. NMR
Sharma AK; Lee SJ; Rigby AC; Townson SA
Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
[TBL] [Abstract][Full Text] [Related]
5. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
6. NMR
Sharma AK; Lee SJ; Zhou M; Rigby AC; Townson SA
Biomol NMR Assign; 2019 Apr; 13(1):227-231. PubMed ID: 30798456
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
8. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
10. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function.
Cao S; Chung S; Kim S; Li Z; Manor D; Buck M
J Biol Chem; 2019 Apr; 294(17):7068-7084. PubMed ID: 30792310
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling.
Yelland T; Garcia E; Parry C; Kowalczyk D; Wojnowska M; Gohlke A; Zalar M; Cameron K; Goodwin G; Yu Q; Zhu PC; ElMaghloob Y; Pugliese A; Archibald L; Jamieson A; Chen YX; McArthur D; Bower J; Ismail S
J Med Chem; 2022 Feb; 65(3):1898-1914. PubMed ID: 35104933
[TBL] [Abstract][Full Text] [Related]
12. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
13. Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel.
Killoran RC; Smith MJ
J Biol Chem; 2019 Jun; 294(25):9937-9948. PubMed ID: 31088913
[TBL] [Abstract][Full Text] [Related]
14. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
15. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
[TBL] [Abstract][Full Text] [Related]
16. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
[TBL] [Abstract][Full Text] [Related]
17. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
18. Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis.
Spoerner M; Hozsa C; Poetzl JA; Reiss K; Ganser P; Geyer M; Kalbitzer HR
J Biol Chem; 2010 Dec; 285(51):39768-78. PubMed ID: 20937837
[TBL] [Abstract][Full Text] [Related]
19. NMR
Yuan C; Hansen AL; Bruschweiler-Li L; Brüschweiler R
Biomol NMR Assign; 2024 Jun; 18(1):7-13. PubMed ID: 37948018
[TBL] [Abstract][Full Text] [Related]
20. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
